A little different video today.

I recently had a heart procedure for AFib called pulsed field ablation, and I decided to share my experience — what it was like, why I did it, and how it’s gone so far.

youtu.be/cLXZ-9Cd8Us #afib #ablation #pulsedfieldablation

Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026 Demonstrating Instantaneous Ablation Through High-Voltage Waveforms and Efficient Point-by-Point Pulsed Field Ablation CARDIFF-BY-THE-SEA, Calif., Feb. 6, 2026 /PRNewswire/ — Field Medical, Inc., a clinical-stage medical technology company advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias, today announced the presentation of late breaking clinical trial data from the first-in-human Field PULSE study at the 31st Annual International AF Symposium 2026, held February 5–7 in Boston. Field PULSE evaluates a novel high-voltage, sub-second pulsed field waveform delivered through Field Medical’s FieldForce™ Ablation System and Catheter, a focal, contact-sensing catheter, enabling instantaneous ablation through point-by-point energy delivery without reliance on prolonged […]

Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026 #AtrialFibrillation #CardiacArrhythmias #PulsedFieldAblation #FieldMedical #ClinicalTrials

FARAWATCH

Address #Afib symptoms and reduce stroke risk in one concomitant streamlined case with the FARAPULSE™ PFA Platform and WATCHMAN FLX™ Pro LAAC Device, also known as FARAWATCH™. Learn more about the #FARAWATCH approach: qrco.de/bgX2uh

#LAAC #PulsedFieldAblation

Wolfe upgrades Medtronic as pulsed field ablation may jolt near term growth Investing.com -- Wolfe Research upgraded Medtronic plc to Peer Perform from Underperform saying that an expected ramp‑up of its Affera pulsed‑field ablation (PFA) system could add up to two percentage points to organic revenue and help the medical‑device maker exceed its own 5% growth target in fiscal 2026. Affera’s contribution means “everything else” would need to grow only about 3‑4% to meet guidance, a level the rest of the portfolio has delivered over the past two quarters, according to analyst. Medtronic (NYSE:MDT) shares are up 1% at $86.9 on Monday, have fallen about 5% since Wolfe first put an Underperform rating on the stock three years ago, lagging the S&P 500 Health Care index by roughly 37 points over that period. The brokerage still sees structural risks, including surgical‑robot competition from Intuitive Surgical (NASDAQ:ISRG) and share losses in diabetes devices. It also warned that Medtronic’s valuation – about 15 times projected 2026 earnings, versus 11 times for other slow‑growth med‑tech peers, could compress if execution slips. Wolfe’s upgrade is not a call that “the stock is fixed forever,” the note said, but reflects a more favourable skew to near‑term estimates thanks to Affera and “a decent‑sized list of lesser good guys” that could give the company a pulse after years of underperformance.

Click Subscribe #Medtronic #PulsedFieldAblation #Healthcare #StockMarket #Investing

Pulsed field ablation is here! Join cardiac electrophysiologist Dr. Sunjeet Sidhu as he dives into this innovative #AFib treatment. Listen to our latest #podcast episode to learn more about its impact on cardiac care 🎧 http://ms.spr.ly/63321Ukyu5 #PulsedFieldAblation